Barely Significant
← all excerpts

BRCA1 Expression and Outcome in Patients With <i>EGFR</i>-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib.

JTO Clin Res Rep · 2021 · PMC8474244 · PMID 34589994

Europe PMCDOI
1
hedged sentence
0.8755
closest p · 17.5× alpha
0.8755
boldest claim

The sentences

did not reach statistical significancep = 0.8755not close (p > 0.1)
In the gefitinib plus olaparib arm, the BRCA1-high group had a longer median PFS of 14.6 months (95% CI: 8.6–20.3) compared with 10.9 months (95% CI: 7.2–36.4) for the BRCA1-low group, although this increase did not reach statistical significance ( p = 0.8755) ( Table 2 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.